Compare Cassava Sciences Inc (FLNA) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Kohl's Corporation — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Kohl's Corporation trades at $20.04 (market cap $2.28B). The key difference: Kohl's Corporation is far larger — about 57.9× Cassava Sciences Inc's market cap, and Kohl's Corporation pays a 2.49% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Kohl's Corporation for 48 Days on average.
| FLNA | KSS | |
|---|---|---|
Market Cap | $39.40M | $2.28B |
Volume | 759,018 | 4,960,280 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $24.71 |
52-Week Low | $0.68 | $11.72 |
Typical Hold Time | 37 Days | 48 Days |
Enterprise Value | -$43.28M | $7.88B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Kohl's (KSS) trades at $20.12, up 2.5% today, with a bullish technical signal driven by moving averages but overbought RSI readings. The stock shows deep value with a P/E of 8.63 and P/B of 0.55, though revenue has declined annually since 2022. Recent Q2 2026 earnings beat estimates with EPS of $1.28, and the company raised full-year guidance, supported by margin gains and a new chief merchandising officer appointment.
The outlook is mixed: low valuation and earnings momentum offer upside, but persistent sales declines and competitive pressures pose risks. Analyst consensus is cautious with a $15.50 price target below the current price, reflecting skepticism about the sustainability of the turnaround amid consumer spending shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
